Effect of Faricimab in Patients with Age-related Macular Degeneration, Exudative Neovascular, Non-responders to other Intravitreal Anti-angiogenic Agents
Keywords:
age-related macular degeneration, neovascula, faricimab, non-responder, optical coherence tomographyAbstract
Objective: To describe the functional and anatomical results of treatment with faricimab in patients with age-related macular degeneration, in its exudative neovascular form, who did not respond to other intravitreal antiangiogenic agents.
Methods: A prospective intervention study was conducted with ten patients with age-related macular degeneration, in its neovascular exudative form, who did not respond to other antiangiogenic agents treated with faricimab and diagnosed as non-responders to other intravitreal antiangiogenic agents, at the Retina Service of the Cuban Institute of Ophthalmology and the Hermanos Ameijeiras Surgical Clinical Hospital, from January 2023 to March 2024. Best-corrected visual acuity, degree of clinical activity, macular thickness in the central subfield, treatment interval after induction, and ocular and systemic complications were evaluated.
Results: The mean best-corrected visual acuity increased from 52 to 68 VAR after induction and remained stable at follow-up. Central macular thickness decreased from baseline to completion of induction and end of the first year of treatment (365 µm, 249 µm to 237 µm). The treatment interval after induction was 12 weeks in 7 patients (70%), 8 weeks in 2 (20%), and 16 weeks in 1 (10%). No drug- or procedure-related ocular adverse events or systemic adverse events were reported.
Conclusions: Treatment with Faricimab in patients with age-related macular degeneration, in its exudative neovascular form, who are non-responders to other antiangiogenic agents represents an effective alternative for disease control, with fewer injections and no treatment-related complications.
Downloads
References
1. Ruiz Moreno JM. Protocolo de diagnóstico, seguimiento y recomendaciones generales en la degeneración macular asociada a la edad (DMAE) precoz e intermedia: consenso de un panel de expertos. Barcelona: Esmon Publicidad, D.L.; 2016.
2. Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, De Jong P, et al. Prevalence of age-related macular degeneration in the United States. Arch ophthalmol. 2004;122(4):564-72. DOI: 10.1001/archopht.122.4.564
3. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):P1-P65. DOI: 10.1016/j.ophtha.2019.09.024
4. Río M, Rodríguez BN, Padilla MC, Barroso R. Encuesta nacional de ceguera y discapacidad visual en el adulto mayor Cuba 2016. La Habana: Instituto Cubano de Oftalmología Ramón Pando Ferrer; 2017 [acceso 01/01/2025] p. 71. Disponible en: https://search.bvsalud.org/gim/resource/es/biblio-972201
5. Rush RB. One-year outcomes of Faricimab treatment for AFLIBERCEPT-resistant Apreciamos mucho su apoyo. No neovascular age-related macular degeneration. Clinical Ophthalmology. 2023:2201-8. DOI: 10.2147/OPTH.S424315.
6. Khanani A, Guymer R, Basu K, Boston H, Heier J, Korobelnik J, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1(4):100076. DOI: 10.1016/j.xops.2021.100076
7. De La Amm PÉ. Declaración de Helsinki de la AMM Principios éticos para las investigaciones médicas en seres humanos. 64ª Asamblea General, Fortaleza, Brasil; 2013. DOI: 10.1001/jama.2013.281053
8. Rio Torres M, Fernández Argones LHS, Juan Raúl, Ramos López M. Oftalmología. Diagnóstico y tratamiento. Segunda edición ed. Oubiña González JM, editor. La Habana, Cuba: Editorial Ciencias Médicas; 2018.
9. Amoaku W, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29(6):721-31. DOI: 10.1038/eye.2015.48
10. Seguin-Greenstein S, Lightman S, Tomkins-Netzer O. A meta‐analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age‐related macular degeneration following switching to treatment with aflibercept. Journal of ophthalmology. 2016;2016(1):4095852. DOI: 10.1155/2016/4095852
11. Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Global experience of faricimab in clinical settings-a review. Expert Opinion on Biological Therapy. 2024;24(4):263-8. DOI: 10.1080/14712598.2024.2336087
12. Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024:1-9.DOI: 10.1038/s41433-024-03364-y
13. Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clinical Ophthalmology. 2023:1287-93. DOI: 10.2147/OPTH.S409822
14. Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmology and Therapy. 2024:1-13. DOI: 10.1007/s40123-024-01036-4
15. Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clinical Ophthalmology (Auckland, NZ). 2022;16:4041. DOI: 10.2147/OPTH.S395279
16. Li G, Zhu N, Ji A. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials. Medicine. 2023;102(50):e36370. DOI: 10.1097/MD.0000000000036370
17. Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study–6 month results. Eye. 2023;37(17):3574-81. DOI: 10.1038/s41433-023-02553-5
18. Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. Journal of Clinical Medicine. 2023;12(15):5145. DOI: 10.3390/jcm12155145
19. Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, Takahashi H, et al. Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history. Ophthalmology and Therapy. 2023;12(5):2703-12. DOI: 10.1007/s40123-023-00779-w
20. Hang A, Ngo T, Virk JS, Moussa K, Moshiri A, Emami-Naeini P, et al. Intravitreal faricimab for previously treated neovascular age-related macular degeneration. Clinical Ophthalmology. 2024:3781-9. DOI: 10.2147/OPTH.S494605
21. Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, et al. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration. Life. 2024;14(2):193. DOI: 10.3390/life14020193.
22. Kenworthy MK, Alexis JA, Ramakrishnan P, Chen FK. Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab. Clinical & Experimental Ophthalmology. 2023. DOI: 10.1111/ceo.14335
23. Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024;262(4):1151-9. DOI: 10.1007/s00417-023-06319-3
24. Larsen HO, Grauslund J, Vergmann AS. Efficacy, durability and safety of faricimab in neovascular age-related macular degeneration and diabetic macular oedema: lessons learned from registration trials. Ophthalmology and Therapy. 2023;12(5):2253-64. DOI: 10.1007/s40123-023-00753-6
25. Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet. 2022;399(10326):729-40. DOI: 10.1016/S0140-6736(22)00010-1.
26. Samacá-Samacá D, Hernández-Castillo C, Prieto-Pinto L, Rodríguez F, Sardi C, Ocampo H, et al. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. BMJ Open Ophthalmology. 2024;9(1):e001702. DOI: 10.1136/bmjophth-2024-001702.
27. Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA. Sterile intraocular inflammation associated with faricimab. JAMA ophthalmology. 2024;142(11):1028-36. DOI: 10.1001/jamaophthalmol.2024.3828
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Cubana de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
El contenido de la revista se encuentra accesible sin costo alguno. Está protegido por los términos de la Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional
